Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1991 Jul;29(7):1376–1381. doi: 10.1128/jcm.29.7.1376-1381.1991

Evaluation of a synthetic-peptide enzyme-linked immunosorbent assay for immunoglobulin M to human parvovirus B19.

E Fridell 1, B J Cohen 1, B Wahren 1
PMCID: PMC270121  PMID: 1653264

Abstract

A synthetic peptide corresponding to a part of the virus protein 1-virus protein 2 overlapping region of human parvovirus B19 was used in an indirect enzyme-linked immunosorbent assay. Antibodies of the immunoglobulin (Ig) M class were measured in serum samples from patients with erythema infectiosum and controls. In comparison with an IgM assay using native B19 viral antigen, the peptide antigen assay was 92% sensitive and 87% specific. B19 IgM reactivities were seen in a limited number of children with other viral diseases. Specific IgM reactivities to short synthetic viral peptides have previously been reported only with Epstein-Barr virus. Since other sources of viral antigen are limited, the peptide antigen assay may be a useful alternative for the diagnosis of B19-associated disease in human beings.

Full text

PDF
1376

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson M. J., Lewis E., Kidd I. M., Hall S. M., Cohen B. J. An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) 1984 Aug;93(1):85–93. doi: 10.1017/s0022172400060964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Azzi A., Macchia P. A., Favre C., Nardi M., Zakrzewska K., Corsi O. B. Aplastic crisis caused by B19 virus in a child during induction therapy for acute lymphoblastic leukemia. Haematologica. 1989 Mar-Apr;74(2):191–194. [PubMed] [Google Scholar]
  3. Bell L. M., Naides S. J., Stoffman P., Hodinka R. L., Plotkin S. A. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989 Aug 24;321(8):485–491. doi: 10.1056/NEJM198908243210801. [DOI] [PubMed] [Google Scholar]
  4. Brown C. S., Salimans M. M., Noteborn M. H., Weiland H. T. Antigenic parvovirus B19 coat proteins VP1 and VP2 produced in large quantities in a baculovirus expression system. Virus Res. 1990 Mar;15(3):197–211. doi: 10.1016/0168-1702(90)90028-a. [DOI] [PubMed] [Google Scholar]
  5. Brown K. E., Buckley M. M., Cohen B. J., Samuel D. An amplified ELISA for the detection of parvovirus B19 IgM using monoclonal antibody to FITC. J Virol Methods. 1989 Nov;26(2):189–198. doi: 10.1016/0166-0934(89)90148-1. [DOI] [PubMed] [Google Scholar]
  6. Cohen B. J., Mortimer P. P., Pereira M. S. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) 1983 Aug;91(1):113–130. doi: 10.1017/s0022172400060095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cossart Y. E., Field A. M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet. 1975 Jan 11;1(7898):72–73. doi: 10.1016/s0140-6736(75)91074-0. [DOI] [PubMed] [Google Scholar]
  8. Cotmore S. F., McKie V. C., Anderson L. J., Astell C. R., Tattersall P. Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol. 1986 Nov;60(2):548–557. doi: 10.1128/jvi.60.2.548-557.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Duermeyer W., Wielaard F., van der Veen J. A new principle for the detection of specific IgM antibodies applied in an ELISA for hepatitis A. J Med Virol. 1979;4(1):25–32. doi: 10.1002/jmv.1890040104. [DOI] [PubMed] [Google Scholar]
  10. Eitrem R., Vene S., Niklasson B. Incidence of sand fly fever among Swedish United Nations soldiers on Cyprus during 1985. Am J Trop Med Hyg. 1990 Aug;43(2):207–211. doi: 10.4269/ajtmh.1990.43.207. [DOI] [PubMed] [Google Scholar]
  11. Evans J. P., Rossiter M. A., Kumaran T. O., Marsh G. W., Mortimer P. P. Human parvovirus aplasia: case due to cross infection in a ward. Br Med J (Clin Res Ed) 1984 Mar 3;288(6418):681–681. doi: 10.1136/bmj.288.6418.681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Frickhofen N., Abkowitz J. L., Safford M., Berry J. M., Antunez-de-Mayolo J., Astrow A., Cohen R., Halperin I., King L., Mintzer D. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): a treatable cause of anemia in AIDS. Ann Intern Med. 1990 Dec 15;113(12):926–933. doi: 10.7326/0003-4819-113-12-926. [DOI] [PubMed] [Google Scholar]
  13. Fridell E., Trojnar J., Mehlin H., Wahren B. A cyclized peptide for studies of human parvovirus B19 infection. J Immunol Methods. 1991 Apr 8;138(1):125–128. doi: 10.1016/0022-1759(91)90072-n. [DOI] [PubMed] [Google Scholar]
  14. Fridell E., Trojnar J., Wahren B. A new peptide for human parvovirus B19 antibody detection. Scand J Infect Dis. 1989;21(6):597–603. doi: 10.3109/00365548909021686. [DOI] [PubMed] [Google Scholar]
  15. Hayward A. R., Lawton A. R. Induction of plasma cell differentiation of human fetal lymphocytes: evidence for functional immaturity of T and B cells. J Immunol. 1977 Oct;119(4):1213–1217. [PubMed] [Google Scholar]
  16. Kajigaya S., Shimada T., Fujita S., Young N. S. A genetically engineered cell line that produces empty capsids of B19 (human) parvovirus. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7601–7605. doi: 10.1073/pnas.86.19.7601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kurtzman G. J., Cohen B. J., Field A. M., Oseas R., Blaese R. M., Young N. S. Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 1989 Oct;84(4):1114–1123. doi: 10.1172/JCI114274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kurtzman G. J., Ozawa K., Cohen B., Hanson G., Oseas R., Young N. S. Chronic bone marrow failure due to persistent B19 parvovirus infection. N Engl J Med. 1987 Jul 30;317(5):287–294. doi: 10.1056/NEJM198707303170506. [DOI] [PubMed] [Google Scholar]
  19. Linde A., Andersson J., Lundgren G., Wahren B. Subclass reactivity to Epstein-Barr virus capsid antigen in primary and reactivated EBV infections. J Med Virol. 1987 Feb;21(2):109–121. doi: 10.1002/jmv.1890210203. [DOI] [PubMed] [Google Scholar]
  20. Morinet F., D'Auriol L., Tratschin J. D., Galibert F. Expression of the human parvovirus B19 protein fused to protein A in Escherichia coli: recognition by IgM and IgG antibodies in human sera. J Gen Virol. 1989 Nov;70(Pt 11):3091–3097. doi: 10.1099/0022-1317-70-11-3091. [DOI] [PubMed] [Google Scholar]
  21. Mortimer P. P., Luban N. L., Kelleher J. F., Cohen B. J. Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet. 1983 Aug 27;2(8348):482–484. doi: 10.1016/s0140-6736(83)90512-3. [DOI] [PubMed] [Google Scholar]
  22. Ozawa K., Young N. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol. 1987 Aug;61(8):2627–2630. doi: 10.1128/jvi.61.8.2627-2630.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Schwarz T. F., Roggendorf M., Hottenträger B., Deinhardt F., Enders G., Gloning K. P., Schramm T., Hansmann M. Human parvovirus B19 infection in pregnancy. Lancet. 1988 Sep 3;2(8610):566–567. doi: 10.1016/s0140-6736(88)92684-0. [DOI] [PubMed] [Google Scholar]
  24. Serjeant G. R., Topley J. M., Mason K., Serjeant B. E., Pattison J. R., Jones S. E., Mohamed R. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981 Sep 19;2(8247):595–597. doi: 10.1016/s0140-6736(81)92739-2. [DOI] [PubMed] [Google Scholar]
  25. Shade R. O., Blundell M. C., Cotmore S. F., Tattersall P., Astell C. R. Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol. 1986 Jun;58(3):921–936. doi: 10.1128/jvi.58.3.921-936.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shirley J. A., Revill S., Cohen B. J., Buckley M. M. Serological study of rubella-like illnesses. J Med Virol. 1987 Apr;21(4):369–379. doi: 10.1002/jmv.1890210409. [DOI] [PubMed] [Google Scholar]
  27. Shneerson J. M., Mortimer P. P., Vandervelde E. M. Febrile illness due to a parvovirus. Br Med J. 1980 Jun 28;280(6231):1580–1580. doi: 10.1136/bmj.280.6231.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Smith R. S., Rhodes G., Vaughan J. H., Horwitz C. A., Geltosky J. E., Whalley A. S. A synthetic peptide for detecting antibodies to Epstein-Barr virus nuclear antigen in sera from patients with infectious mononucleosis. J Infect Dis. 1986 Nov;154(5):885–889. doi: 10.1093/infdis/154.5.885. [DOI] [PubMed] [Google Scholar]
  29. Sundqvist V. A. Frequency and specificity of varicella zoster virus IgM response. J Virol Methods. 1982 Nov;5(3-4):219–227. doi: 10.1016/0166-0934(82)90012-x. [DOI] [PubMed] [Google Scholar]
  30. Sundqvist V. A., Wahren B. An interchangeable ELISA for cytomegalovirus antigen and antibody. J Virol Methods. 1981 Apr;2(5):301–312. doi: 10.1016/0166-0934(81)90029-x. [DOI] [PubMed] [Google Scholar]
  31. Van Elsacker-Niele A. M., Salimans M. M., Weiland H. T., Vermey-Keers C., Anderson M. J., Versteeg J. Fetal pathology in human parvovirus B19 infection. Br J Obstet Gynaecol. 1989 Jul;96(7):768–775. doi: 10.1111/j.1471-0528.1989.tb03314.x. [DOI] [PubMed] [Google Scholar]
  32. Weiland H. T., Salimans M. M., Fibbe W. E., Kluin P. M., Cohen B. J. Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant patient. Br J Haematol. 1989 Feb;71(2):300–300. doi: 10.1111/j.1365-2141.1989.tb04276.x. [DOI] [PubMed] [Google Scholar]
  33. Weiland H. T., Vermey-Keers C., Salimans M. M., Fleuren G. J., Verwey R. A., Anderson M. J. Parvovirus B19 associated with fetal abnormality. Lancet. 1987 Mar 21;1(8534):682–683. doi: 10.1016/s0140-6736(87)90442-9. [DOI] [PubMed] [Google Scholar]
  34. Yaegashi N., Shiraishi H., Tada K., Yajima A., Sugamura K. Enzyme-linked immunosorbent assay for IgG and IgM antibodies against human parvovirus B19: use of monoclonal antibodies and viral antigen propagated in vitro. J Virol Methods. 1989 Nov;26(2):171–181. doi: 10.1016/0166-0934(89)90146-8. [DOI] [PubMed] [Google Scholar]
  35. Young N. Hematologic and hematopoietic consequences of B19 parvovirus infection. Semin Hematol. 1988 Apr;25(2):159–172. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES